There are patches for quitting smoking, and patches for birth control — so why not a patch for ADHD? Early clinical trials suggest that a methylphenidate transdermal system (MTS), or patch, demonstrated statistically significant reductions in the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) and was generally well tolerated in patients aged 6 to 12.
A routine FDA review uncovered unexpected reports of psychiatric side effects resulting from the use of methylphenidate (Concerta, Ritalin), including several that have not been explicitly labeled, such as suicidal thoughts, hallucinations and violent behavior. The US agency says it intends to strengthen the labeled warnings for all methylphenidate products and is investigating whether similar behaviors are seen with other ADHD treatments, such as Adderall and Strattera.
Over eight million adult Americans, or 4.3 percent of working-age adults, struggle with the inattention, impulsivity and hyperactivity of ADHD. According to an analysis presented at the American Psychiatric Association’s annual meeting in Atlanta, attention-deficit/hyperactivity disorder (ADHD) costs U.S. households nearly $77 billion in lost income every year.
Information on attention-deficit/hyperactivity disorder specifically in children provides background on signs, prevalence and causes of ADHD, as well as offering suggestions on help available for families.
We comply with the HONcode standard for trustworthy health information: verify here.
